newsfilter
← Latest News
GlobeNewswire·

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

  • Kura Oncology granted inducement stock options to three new employees on November 2, 2026, under its 2023 Inducement Option Plan.
  • The total award consists of 55,500 nonstatutory stock options to purchase common stock, approved as material inducement under Nasdaq Listing Rule 5635(c)(4).
  • Each option has an exercise price of $9.79 per share, based on the closing stock price on the grant date.
  • Vesting occurs over four years, with 25% of shares vesting on the one-year anniversary 36-month monthly vesting thereafter contingent on continued service.
  • The awards are subject to the terms of the Company's 2023 Inducement Option Plan 36-month stock option agreements.
  • Kura Oncology is a biopharmaceutical company developing precision medicines for cancer, including the FDA-approved drug KOMZIFTI for NPM1-mutated acute myeloid leukemia.
Company
Kura Oncology, Inc.
Keywords
Nasdaq:KURA, Kura Oncology, Inc.